LVTX News and Press, LAVA Therapeutics N.V. From 02/29/24

2024-02-29 14:24:12 ET DENVER, Colo., Feb 29, 2024 ( 247marketnews.com )- After quietly trading sideways, today, Lava Therapeutics N.V. (NASDAQ: LVTX ) shot straight up from below $2.25 to a high of $3.41. It’s pulled back to $3.12, up $0.96 (+44.44%), 3.4M shares. LVTX&#...

2024-01-26 09:19:36 ET Losers: TC BioPharm ( TCBP ) -21% . Mobilicom Limited ( MOB ) -21% announces $2.95 Million registered direct offering . LAVA Therapeutics ( LVTX ) -14% . Evaxion Biotech ( EVAX ) -13% . Nxu ( NXU ) -13% ...

2024-01-25 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-25 08:11:38 ET More on LAVA Therapeutics Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics Read the full article on Seeking Alpha For further det...

2024-01-25 07:32:06 ET DENVER, Colo., Jan. 25, 2023 (www.247marketnews.com)- LAVA Therapeutics NV (NASDAQ: LVTX) stated, this morning, that... For further details see: LAVA Therapeutics (NASDAQ: LVTX) is Flowing on Merck Collaboration News

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAV...

2023-11-16 07:17:43 ET More on LAVA Therapeutics Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics For further details see: LAVA Therapeutics GAAP EPS of -$0...

LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2 Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody ® platform as a monotherapy in advanced EGFR expres...

The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...

LAVA Therapeutics N.V. (LVTX) is expected to report $-0.48 for Q3 2023